SW VandeCarr
- 2,199
- 77
ApplePion said:There are lots of things you cannot randomize.
Of course. You do the best you can, but you may not get the most convincing results.
Last edited:
ApplePion said:There are lots of things you cannot randomize.
ApplePion said:It often does, but not always. What I do believe is that everytime I have seen someone object that causation does not imply correlation, that person was arguing against something where the correlation was clealy causal. (Ironically, that is an interesting correlation.)
We know that the relationship between LDL cholesterol and heart disease is causal because it occurs through all subgroups of people with elevated LDL, and because almost any way of lowering itlowers risk. This is unlike the correlation between coffee and lung cancer--the elevation is found only in one subgroup--smokers--and so we know it is not really coffee that is the cause. In the coffee case, the coffee is not harmful, but rather is correlated with the thing that is really harmful. But it does not work that way with cholesterol--the correlation with heart disease is unrestricted.
Please quote what you are referring to so that we don't have to guess.SW VandeCarr said:This is in the first few paragraphs of the 2002 "cholesterol skeptic" paper that I posted and to which you seem to object to so much. I don't accept their full thesis, but they seem to have gotten that one right. They also claim that the method of measuring arterial wall media-intima thickness is inaccurate. I don't have an opinion on that.
Evo said:Please quote what you are referring to so that we don't have to guess.
Thanks.
SW VandeCarr said:I think the central issue in this thread is the recent evidence that cholesterol is not the whole story in CVD (CRP, inflammation, thrombus explanation)
SW VandeCarr said:It is for this reason that antiatherosclerotic therapy (including lipid-lowering therapy) should be aggressive in patients with CHD or at high CHD risk. The most dangerous lesions are nonocclusive, asymptomatic, and not necessarily detected by stress testing, with or without imaging, or by coronary arteriography because the lesions may be accompanied by compensatory dilation with little or no encroachment on the lumen (6)."
ApplePion said:Doesn't this contradict your original claim that seemingly healthy people with high cholesterol should not be given medication to lower cholesterol
RE: It is for this reason that antiatherosclerotic therapy (including lipid-lowering therapy) should be aggressive in patients with CHD or at high CHD risk. The most dangerous lesions are nonocclusive, asymptomatic, and not necessarily detected by stress testing, with or without imaging, or by coronary arteriography because the lesions may be accompanied by compensatory dilation with little or no encroachment on the lumen (6)."
ApplePion said:What I claimed was that people with increased cholesterol are at increased risk for heart disease
SW VandeCarr said:Does having heart disease or being at high risk sound healthy to you?
SW VandeCarr said:I agree that if they are symptomatic or have arterial blockage on testing, they should be treated with statins, but not if it's just a laboratory value and no other interventions have been tried.
ApplePion said:Does the term "seemingly healthy" sound like "healthy" to you?
ApplePion said:I never claimed that cholesterol is the whole story--smoking, high blood pressure and diabetes are other factors. Indeed, smoking is a much more important factor for heart disease. Nor is the evidence "recent" that cholesterol is not the whole thing. What I claimed was that people with increased cholesterol are at increased risk for heart disease.
ApplePion said:Does the term "seemingly healthy" sound like "healthy" to you?
ApplePion said:Are you not aware that you were responding to a post where I specifically quoted your post saying that often people with severe heart disease are completely undiagnosable because they have no symptoms and their disease will not show up on tests?
If you are not aware that you posted it, you should carefully look at my post labelled #37, where I quote you.
SW VandeCarr said:What you've been claiming was that high cholesterol caused CVD. Now you're saying that it increases the risk, which is correct. These concepts need to be distinguished by scientists if not lay people. High serum cholesterol is neither a necessary or sufficient cause of CVD.
SW VandeCarr said:What does seemingly healthy mean? In the absence of more information, if a person appears healthy from what ever information base we have, should we assume that the person is not healthy?
ApplePion said:If someone appears healthy but otherwise has high cholesterol we should assume he might be unhealthy.
In fact, that was a recommendation of a paper you yourself posted.
Do you also think that people with high blood pressure who seem healthy should not get their blood pressure under control?
Just to comment on this issue. The 3 studies mentioned before by ApplePion (HPS, PROSPER and the prospective Cardiovascular Health Study (CHS) are not particularly convincing, in my opinion.SW VandeCarr said:Despite what I said, I must respond to this because it is so obviously wrong. I never said high cholesterol in "healthy" people should not be treated.
Statins and All-Cause Mortality in High-Risk Primary PreventionIn conclusion, based on aggregate data on 65 229 men and women from 11 studies, yielding approximately 244 000 person-years of follow-up and 2793 deaths, we observed that statin therapy for an average period of 3.7 years had no benefit on all-cause mortality in a high-risk primary prevention population. Current prevention guidelines endorse statin therapy for subjects at high global risk of incident CVD as a means to reduce fatal and nonfatal vascular events. Due consideration is needed in applying statin therapy in lower-risk primary prevention populations.
Statins for the primary prevention of cardiovascular disease.Although reductions in all-cause mortality, composite endpoints and revascularisations were found with no excess of adverse events, there was evidence of selective reporting of outcomes, failure to report adverse events and inclusion of people with cardiovascular disease. Only limited evidence showed that primary prevention with statins may be cost effective and improve patient quality of life. Caution should be taken in prescribing statins for primary prevention among people at low cardiovascular risk.
Similarily,Published pharmaceutical industry–sponsored trials are more likely than non-industry sponsored trials to report results and conclusions that favor drug over placebo.
Factors Associated with Findings of Published Trials of Drug–Drug Comparisons: Why Some Statins Appear More Efficacious than OthersRCTs of head-to-head comparisons of statins with other drugs are more likely to report results and conclusions favoring the sponsor’s product compared to the comparator drug. This bias in drug–drug comparison trials should be considered when making decisions regarding drug choice.